Drug Trial Radar · NCT01553747
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
Last checked: Nov 20, 2026Latest source record: Jul 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,146
Actual
Start
May 29, 2012
Primary completion
Jan 9, 2014
Study completion Jan 9, 2014
Sponsor
- Lead sponsor
- Furiex Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 14, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.
Conditions
- Irritable Bowel Syndrome
Interventions
EluxadolineDrug
Oral tablets twice daily
PlaceboDrug
Oral tablets twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency ScoresTime frame: Up to 12 weeks
Locations
253 sites in 4 countries. Site status is shown where the registry gives one.
Furiex Research Site
Birmingham, Alabama
Furiex Research Site
Birmingham, Alabama
Furiex Research Site
Decatur, Alabama
Furiex Research Site
Huntsville, Alabama
Furiex Research Site
Mobile, Alabama
Furiex Research Site
Montgomery, Alabama
Furiex Research Site
Sheffield, Alabama
Furiex Research Site
Tuscaloosa, Alabama
Furiex Research Site
Glendale, Arizona
Furiex Research Site
Glendale, Arizona
Furiex Research Site
Mesa, Arizona
Furiex Research Site
Phoenix, Arizona
Furiex Research Site
Phoenix, Arizona
Furiex Research Site
Tucson, Arizona
Furiex Research Site
Tucson, Arizona
Furiex Research Site
Jonesboro, Arkansas
Furiex Research Site
Little Rock, Arkansas
Furiex Research Site
Sherwood, Arkansas
Furiex Research Site
Anaheim, California
Furiex Research Site
Chula Vista, California
Furiex Research Site
Encinitas, California
Furiex Research Site
Garden Grove, California
Furiex Research Site
Huntington Beach, California
Furiex Research Site
Irvine, California
Furiex Research Site
La Mesa, California
Furiex Research Site
La Mirada, California
Furiex Research Site
Laguna Hills, California
Furiex Research Site
Lakewood, California
Furiex Research Site
Lincoln, California
Furiex Research Site
Loma Linda, California
Furiex Research Site
Lomita, California
Furiex Research Site
Long Beach, California
Furiex Research Site
Los Angeles, California
Furiex Research Site
Newport Beach, California
Furiex Research Site
North Hollywood, California
Furiex Research Site
Northridge, California
Furiex Research Site
Pasadena, California
Furiex Research Site
Sacramento, California
Furiex Research Site
San Diego, California
Furiex Research Site
San Diego, California
Showing 40 of 253 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.